The structure of afferent neurons is pseudounipolar. Studies suggest that they relay action potentials (APs) to both directions of the T-junctions to reach the cell body and the spinal cord. Moreover, the somata are electrically excitable and shown to be able to transmit the signals to associated satellite cells. Our study demonstrates that this transmission can go further and pass onto passive neighbouring somata, if they are in direct contact with same satellite cells. The neurons activate the satellite cells by releasing ATP. This triggers the satellite cells to exocytose acetylcholine to the neighbouring neurons. In addition, the ATP inhibits the nicotinic receptors of the neurons by activating P2Y receptors and initiating the G-protein-mediated pathway, thus reducing the signals that return to the neurons that initiated the signals. This “sandwich synapse” represents a unique pathway by the ectopic release between the somata and the satellite cells.

The symptoms of Parkinson's disease occur due to degeneration of dopamine neurons in substantia nigra. It has been demonstrated that glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor when it comes to protect and enhance survival of dopamine neurons in animal models of Parkinson's disease. The aim of this study was to evaluate short- and long-term effects of GDNF on survival and nerve fiber outgrowth of dopamine cells and astrocytic migration in mouse fetal ventral mesencephalic (VM) tissue. Primary tissue cultures were made of mouse fetal VM tissue and evaluated at 7 and 21 days in vitro (DIV) in terms of dopaminergic nerve fiber outgrowth and astrocytic migration when developed with GDNF present, partially, or completely absent. The results revealed that VM tissue cultured in the absence of GDNF did not exhibit any significant differences in migration of astrocytes or dopaminergic nerve fiber outgrowth neither after 7 DIV nor after 21 DIV, when compared with tissue cultured with GDNF present. Migration of astrocytes and dopaminergic nerve fiber outgrowth reached longer distances when tissue was left to develop for 21 DIV in comparison with 7 DIV. In order to study the long-term effects of GDNF, mouse fetal dopaminergic tissue was transplanted into the ventricles of adult mice and evaluated after 6 months. No surviving dopamine neurons were present in the absence of GDNF. In contrast dopamine neurons developed with GDNF did survive, indicating that GDNF is an essential neurotrophic factor when it comes to long-term dopamine cell survival. More cases have to be assessed in the future in order to strengthen the findings. Thus, transplanted dopamine neurons will be assessed after 3 and 12 months in order to map out when dopamine neurons deprived of GDNF undergo degeneration.

Diss. (sammanfattning) Umeå : Univ., 2008. / Härtill 5 uppsatser.

Thesis (Ph.D.). / Written for the Dept. of Experimental Medicine. Title from title page of PDF (viewed 2008/01/12). Includes bibliographical references.

In the teleost brain, radial glial cells (RGCs) are the main macroglia and are stem- like progenitors that express key steroidogenic enzymes, including the estrogen- synthesizing enzyme, aromatase B (cyp19a1b). As a result, RGCs are integral to neurogenesis and neurosteroidogenesis in the brain, however little is known about the permissive factors and signaling mechanisms that control these functions. The aim of this thesis is to investigate if the secretogranin-derived neuropeptide secretoneurin (SN) can exert regulatory control over goldfish (Carassius auratus) RGCs. Immunohistochemistry revealed a close neuroanatomical relationship between RGCs and soma of SNa- immunoreactive magnocellular and parvocellular neurons in the preoptic nucleus in both goldfish and zebrafish (Danio rerio) models. Both intracerebroventricular injections of SNa into the third brain ventricle and SNa exposures of cultured goldfish RGCs in vitro show that SNa can reduce cyp19a1b expression, thus implicating SNa in the control of neuroestrogen production. RNA-sequencing was used to characterize the in vitro transcriptomic responses elicited by 1000 nM SNa in RGCs. These data revealed that gene networks related to central nervous system function (neurogenesis, glial cell development, synaptic plasticity) and immune function (immune system activation, leukocyte function, macrophage response) were increased by SNa. A dose-response study using quantitative proteomics indicates a low 10 nM dose of SNa increased expression of proteins involved in cell growth, proliferation, and migration whereas higher doses down- regulated proteins involved in these processes, indicating SNa has dose-dependent regulatory effects. Together, through these altered gene and protein networks, this thesis proposes SNa exerts trophic and immunogenic effects in RGCs. These datasets identified a total of 12,180 and 1,363 unique transcripts and proteins, respectively, and demonstrated that RGCs express a diverse receptor and signaling molecule profile. Therefore, RGCs can respond to and synthesize an array of hormones, peptides, cytokines, and growth factors, revealing a multiplicity of new functions critical to neuronal-glial interactions.

No description available.

Yes / Background: Riluzole is a neuroprotective drug used in the treatment of motor neurone disease. Recent evidence suggests that riluzole can up-regulate the expression and activity of the astrocyte glutamate transporter, GLT-1. Given that regulation of glutamate transport is predicted to be neuroprotective in Parkinson’s disease, we tested the effect of riluzole in parkinsonian rats which had received a unilateral 6-hydroxydopamine injection into the median forebrain bundle. Results: Rats were treated with intraperitoneal riluzole (4 mg/kg or 8 mg/kg), 1 hour before the lesion then once daily for seven days. Riluzole produced a modest but significant attenuation of dopamine neurone degeneration, assessed by suppression of amphetamine-induced rotations, preservation of tyrosine hydroxylase positive neuronal cell bodies in the substantia nigra pars compacta and attenuation of striatal tyrosine hydroxylase protein loss. Seven days after 6-hydroxydopamine lesion, reactive astrocytosis was observed in the striatum, as determined by increases in expression of glial fibrillary acidic protein, however the glutamate transporter, GLT-1, which is also expressed in astrocytes was not regulated by the lesion. Conclusions: The results confirm that riluzole is a neuroprotective agent in a rodent model of parkinson’s disease. Riluzole administration did not regulate GLT-1 levels but significantly reduced GFAP levels, in the lesioned striatum. Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective effects of this drug.

Yes / Background: Platelet rich plasma (PRP), processed from autologous peripheral blood, is used to treat androgenetic alopecia (AGA). Objective: To determine the efficacy of PRP for hair growth promotion in AGA patients in a randomized, blinded, placebo controlled, pilot clinical trial (NCT02074943). Methods: The efficacy of an 8 week, 5 session, PRP treatment course was determined by measuring hair density and hair caliber changes in 10 AGA affected patients. For each PRP sample, the concentrations of selected growth factors were determined using a multiplex assay system. The clinical results were then correlated to the growth factor concentrations in PRP. Results: At 16 weeks, 8 weeks after the last PRP injection, treated areas exhibited increased mean hair density (+12.76%) over baseline compared to placebo (+0.99%). Mean hair caliber decreased in both treated and placebo regions (-16.22% and -19.46% respectively). Serial analysis of PRP significant variability in concentrations between patients. Overall, there was a positive correlation between GDNF concentration and hair density (p= 0.004). Trends, though not statistically significant, were also observed for FGF2 and VEGF. Limitations: Small sample size and lack of comparative cohorts receiving protocol variations limit confidence in the study data. Conclusions: This small pilot clinical trial suggests PRP treatment may be beneficial for AGA. However, the variable hair growth responses between patients indicate there is a significant opportunity to improve PRP therapy protocols for hair growth promotion. The variability in growth factor concentration in PRP suggests standardization of growth factors post-processing might improve hair growth responses. / RepliCel Life Sciences Inc. (Canada)

Evidências indicam uma interação na comunicação glia-neurônio. E sabido que a isquemia e reperfusão intestinal (I/R) são eventos clínicos graves. Este projeto visa estudar os efeitos de Brilliant Blue G (BBG) e de Probenecida (PB) nas células gliais entéricas (CGE). Os vasos ileais foram ocluídos por 45 min. Os períodos de reperfusão foram de 24 h, 14 e 28 dias.Os animais foram tratados com BBG, PB ou Salina. Os dados mostraram que o receptor P2X7 estava em CEG e neurônios, que há fenótipos diferentes de CGE e Panx-1 estava em CEG (GFAP). As densidades mostraram diminuição do número de células-IR ao receptor P2X7, Panx-1 e Hu no grupo I/R Salina, porém nos grupos tratados houve recuperação do número dessas células e com as CGE ocorreu um aumento no grupo I/R Salina. A área do perfil celular apresentou alterações em neurônios e CGE. Houve alterações na expressão proteica de P2X7 e Panx-1 e na atividade contrátil do intestino. O uso de BBG e de PB têm sido eficaz na recuperação de CGE e neurônios e podem ser alvos terapêuticos para doenças do trato gastrintestinal. / Evidence indicates an interaction in glia-neuron communication. It is known that intestinal ischemia and reperfusion (I/R) are serious clinical events. This project aims to study the effects of Brilliant Blue G (BBG) and Probenecida (PB) on enteric glial cells (CGE). The ileal vessels were occluded for 45 min. Reperfusion periods were 24 h, 14 and 28 days. Animals were treated with BBG, PB or Saline. The data showed that the P2X7 receptor was in CEG and neurons, that there are different phenotypes of CGE and Panx-1 was in CEG (GFAP). The densities showed a decrease in the number of cells-IR to the P2X7 receptor, Panx-1 and Hu in the Salina I/R group, but in the treated groups there was a recovery in the number of these cells and with the CGE there was an increase in the Salina I/R group. The cell profile area presented changes in neurons and CGE. There were changes in the protein expression of P2X7 and Panx-1 and in the contractile activity of the intestine. The use of BBG and PB has been effective in the recovery of CGE and neurons may be therapeutic targets for diseases of the gastrointestinal tract.

Le récepteur atypique ACKR3 et le récepteur CXCR4 sont des récepteurs couplés aux protéines G appartenant à la famille des récepteurs CXC des chimiokines. Ces deux récepteurs sont activés par la chimiokine CXCL12 et sont surexprimés dans de nombreux cancers comme les gliomes, dont ils favorisent la prolifération et le caractère invasif. Le récepteur CXCR4 active des voies de signalisation qui dépendent de la protéine Gi et des β-arrestines et s’associe à plusieurs protéines impliquées dans la transduction du signal, le trafic et la localisation cellulaire du récepteur. Par contre, les mécanismes de signalisation impliqués dans les effets d’ACKR3 restent mal connus. Le récepteur déclenche une signalisation dépendant des β-arrestines, mais son couplage aux protéines G dépend du type cellulaire ou se fait par un mécanisme indirect via son association au récepteur CXCR4. Le récepteur ACKR3 s’associe également au récepteur de l’EGF pour induire la prolifération cellulaire par un mécanisme indépendant de sa stimulation par un agoniste. Ces données illustrent l’intérêt de caractériser de façon systématique l’interactome de ces récepteurs pour comprendre leurs rôles physiologiques et pathologiques. Cette thèse a poursuivi cet objectif grâce à la mise en œuvre d’une approche protéomique combinant la purification des partenaires des deux récepteurs par affinité suivie de leur identification par spectrométrie de masse. J’ai ainsi identifié respectivement 19 et 151 partenaires protéiques potentiels des récepteurs CXCR4 et ACKR3 exprimés dans les cellules HEK-293T. Parmi les protéines recrutées par ACKR3, nous nous sommes focalisés sur la connexine 43 (Cx43, une des protéines constituant les jonctions Gap) du fait de la similitude des effets du récepteur et de la Cx43 dans la pénétration des leucocytes dans le parenchyme cérébral, la migration des interneurones et la progression des gliomes. J’ai confirmé par Western blot et par BRET l’association spécifique de la Cx43 à l’ACKR3 et non pas au CXCR4. De la même façon, j’ai montré une co-localisation de la Cx43 et de l’ACKR3 dans des cellules de gliome humain, ainsi que dans les astrocytes de la zone sous-ventriculaire et les pieds astrocytaires entourant les capillaires cérébraux chez la souris, suggérant que les deux protéines forment un complexe protéique dans un contexte biologique authentique. Des études fonctionnelles ont révélé que l’ACKR3 module les fonctions de la Cx43 par différents mécanismes. L’expression de l’ACKR3 dans les cellules HEK-293T (mimant la surexpression du récepteur dans les tumeurs), induit par elle-même une inhibition de l’activité jonctionnelle de la Cx43. De même, la stimulation du récepteur par un agoniste réduit l’activité jonctionnelle de la Cx43 par un mécanisme impliquant l’activation d’une protéine Gi, la β-arrestine2 et l’internalisation de la Cx43. Cette thèse établit donc pour la première fois un lien fonctionnel entre le système constitué par les chimiokines CXCL11, CXCL12 et leur récepteur ACKR3 d’une part et les jonctions Gap d’autre part qui pourrait jouer un rôle critique dans la progression des gliomes. / The Atypical Chemokine Receptor 3 (ACKR3) and CXCR4 are two G protein-coupled receptors (GPCR) belonging to the CXC chemokine receptor family. Both receptors are activated upon CXCL12 binding and are over-expressed in various tumours, including glioma, where they have been found to promote proliferation and invasive behaviours. Upon CXCL12 binding, CXCR4 activates canonical GPCR signalling pathways involving Gαi protein and β-arrestins. In addition, CXCR4 was found to interact with several proteins able to modify its signalling, trafficking and localization. In contrast, the cellular pathways underlying ACKR3-dependent effects remain poorly characterized. Several reports show that ACKR3 engages β-arrestin-dependent signalling pathways, but its coupling to G proteins is restricted to either specific cellular populations, including astrocytes, or occurs indirectly via its interaction with CXCR4. ACKR3 also associates with the epidermal growth factor receptor to promote proliferation of tumour cells in an agonist-independent manner. These examples suggest that the extensive characterization of ACKR3 and CXCR4 interactomes might be a key step in understanding or clarifying their roles in physiological and pathological contexts. This thesis addressed this issue employing an affinity purification coupled to high-resolution mass spectrometry proteomic strategy that identified 19 and 151 potential protein partners of CXCR4 and ACKR3 transiently expressed in HEK-293T cells, respectively. Amongst ACKR3 interacting proteins identified, we paid particular attention on the gap junction protein Connexin-43 (Cx43), in line with its overlapping roles with the receptor in the control of leukocyte entry into the brain, interneuron migration and glioma progression. Western blotting and BRET confirmed the specific association of Cx43 with ACKR3 compared to CXCR4. Likewise, Cx43 is co-localized with ACKR3 but not CXCR4 in glioma initiating cell lines, and ACKR3 and Cx43 are co-expressed in astrocytes of the sub-ventricular zone and surrounding blood vessels in adult mouse brain, suggesting that both proteins form a complex in authentic cell or tissue contexts. Further functional studies showed that ACKR3 influences Cx43 trafficking and functionality at multiple levels. Transient expression of ACKR3 in HEK-293T cells to mimic ACKR3 overexpression detected in several cancer types, induces Gap Junctional Intercellular Communication (GJIC) inhibition in an agonist-independent manner. In addition, agonist stimulation of endogenously expressed ACKR3 in primary cultured astrocytes inhibits Cx43-mediated GJIC through a mechanism that requires activation of Gαi protein, and dynamin- and β-arrestin2-dependent Cx43 internalisation. Therefore, this thesis work provides the first functional link between the CXCL11/CXCL12/ACKR3 axis and gap junctions that might underlie their critical role in glioma progression.